Key Highlights

  • The FDA told BioCardia its ongoing CardiAMP HF II trial may count as a second supporting study for Premarket Approval, potentially pairing with already-completed data to support US approval for ischemic heart failure.
  • Japan's PMDA issued a supportive Record of Advice for a fourth-quarter Marketing submission built on three completed CardiAMP trials, targeting roughly 20,000 initially eligible patients in a market with reimbursement precedent near $124,000 per procedure.
  • The company resolved a Nasdaq stockholders' Equity deficiency through an at-the-market raise of roughly $4.9 million net, but remains under monitoring through an October 7, 2026 compliance deadline.

BioCardia, Inc. (NASDAQ:BCDA) has done something small-cap cell therapy developers rarely manage: turned years of clinical work into a dated regulatory filing. The company is preparing a marketing application in Japan for CardiAMP, its autologous cell therapy for ischemic heart failure, in the fourth quarter.

That plan sits alongside a separate signal from the US Food and Drug Administration, which told the company its CardiAMP Heart Failure II study may count toward a Premarket Approval - the most demanding clearance route the agency applies.

The regulatory news arrived against a strained balance sheet. BioCardia disclosed a Nasdaq stockholders equity deficiency in April, raised equity to fix it, and reported second quarter results on 12 August 2026 showing $4.1 million of cash. The shares have recently traded below $1.

What Happened

On 5 June 2026, BioCardia said minutes from a meeting with the FDA's Center for Biologics Evaluation and Research confirmed that CardiAMP HF II may support a Premarket Approval application in ischemic heart failure with reduced ejection fraction, or HFrEF - heart failure in which the heart pumps out less blood than it should.

The agency generally prefers two well-designed trials for a broad indication. Under the framework BioCardia described, the completed CardiAMP HF trial serves as the first supporting study and HF II as the second. Chief Executive Peter Altman said the FDA recognises the strengths in the completed data.

A week earlier, Japan's Pharmaceuticals and Medical Devices Agency issued a supportive Record of Advice endorsing a Shonin submission - Japan's equivalent of a premarket approval - built on three completed CardiAMP trials. BioCardia plans to file in the fourth quarter and to engage a Designated Marketing Authorization Holder.

PMDA attached conditions: evidence that enrolled patients were on guideline-directed medication and ineligible for revascularisation, detailed data on deaths, transplants and heart-pump implants, and a commitment to post-marketing study.

Why It Matters

Japan matters disproportionately for a company this size. BioCardia estimates roughly 20,000 of Japan's approximately 300,000 ischemic heart failure patients would initially qualify - those with elevated NTproBNP, a marker of cardiac strain, who are stable on medication but cannot be revascularised. Its June stockholder letter cited precedent reimbursement near $124,000 per procedure.

The US pathway is slower but larger. BioCardia puts the American ischemic HFrEF population above one million patients, and the FDA has already accepted CardiAMP as safe enough to allow Medicare reimbursement for its heart failure trials.

The Numbers

For the three months to 30 June 2026, BioCardia reported a net loss of $1.6 million, narrower than the $2.0 million a year earlier. Research and Development spending fell to $0.9 million from $1.4 million and administrative costs held at $0.7 million. Operating cash use was $1.7 million.

Cash stood at $4.1 million at 30 June, which the company said supports a runway into 2027 - a recovery from the first quarter, when cash had fallen to $951,000 from $2.5 million at the end of 2025. A Form 8-K filed 12 June disclosed the sale of 4,004,330 shares between 1 April and 5 June under an at-the-market agreement for roughly $4.9 million net, including about $4.4 million gross from 3,509,604 shares at an average $1.279, with no warrants attached.

Open-label results from the CardiAMP Chronic Myocardial Ischemia trial were presented at EuroPCR in May by Dr Amish Raval of the University of Wisconsin. Patients with severe refractory angina who had exhausted stent and surgical Options improved exercise tolerance by an average of 179 seconds, sustained through two years, and reported an average 82% reduction in angina episodes at six months, with no major adverse cardiac events.

What It Means for the Company

BioCardia is trying to convert one platform into several Revenue routes. Beyond CardiAMP itself, the Helix transendocardial delivery catheter - a device with a helical needle that screws into the heart wall to inject therapies directly into muscle - is positioned as a tool other developers can license.

On 8 May the company said the FDA had outlined two routes for Helix: clearance alongside CardiAMP, or an independent De Novo pathway, with no safety or performance concerns raised. Management said it is in early discussions with eight gene and cell therapy programmes for cardiac indications. BioCardia also holds two FDA-cleared investigational new drug applications for allogeneic stem cell programmes.

Risks Investors Should Watch

Listing compliance is the nearest-term concern. BioCardia received a Nasdaq notice on 10 April 2026 that stockholders equity had fallen below the $2.5 million minimum under Rule 5550(b)(1). Nasdaq accepted a remediation plan and granted an extension to 7 October 2026. The company said in June it believed the raise had restored compliance, but Nasdaq will keep monitoring and can move toward delisting if the standard is not demonstrated.

A sustained sub-dollar share price could also raise questions under Nasdaq's separate minimum bid price rule; BioCardia carried out a 1-for-15 reverse split in May 2024. Dilution is structural: with roughly 11.4 million shares outstanding and a quarterly burn near $1.7 million, each raise is large relative to the float, and runway guidance depends partly on Warrant holders exercising for cash.

The clinical and regulatory risks are real. PMDA has issued advice, not an approval. CardiAMP HF II is enrolling at only four active sites. The angina results come from an open-label cohort with no blinded control arm, which limits the weight they can carry.

What Comes Next

The Japan Shonin submission in the fourth quarter is the defining milestone, and naming a Designated Marketing Authorization Holder is a step to watch ahead of it. BioCardia also expects a manuscript publication of the CardiAMP HF trial.

In the United States, the priorities are enrolling CardiAMP HF II, adding sites beyond the current four, and deciding whether to pursue the independent De Novo route for Helix. The 7 October Nasdaq deadline and third quarter results will show whether the Balance Sheet repair holds.

Conclusion

BioCardia has turned years of clinical work into two dated regulatory paths at once, a genuinely rare feat for a company this small, with the Japan filing offering a faster, more targeted route to revenue than the larger but slower US pathway. Both depend on execution the company doesn't fully control: PMDA's advice isn't an approval, and CardiAMP HF II is enrolling at only four sites. The balance sheet repair through the at-the-market raise bought time, but the October 7 Nasdaq compliance deadline and the fourth-quarter Japan submission are now on the same calendar, and neither slipping is built into the current cash runway.